According to filings with the U.S. Securities and Exchange Commission, Cantai Therapeutics is raising up to $3,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cantai Therapeutics
Cantai Therapeutics, also known as Cantai Tx, is a company focused on developing innovative treatments for autoimmune diseases. The company specializes in building high-value, rationally designed bispecific antibodies. Their approach involves combining clinically validated mechanisms to achieve superior outcomes for patients suffering from autoimmune conditions. Cantai Therapeutics aims to provide advanced therapeutic solutions through its targeted bispecific antibody technology.

To learn more about Cantai Therapeutics, visit https://cantaitx.com/
Cantai Therapeutics Linkedin Page: https://www.linkedin.com/company/cantai/

Contact:
Ross Leimberg, Chief Operating Officer
603-996-1218
https://www.linkedin.com/in/ross-leimberg-a468654/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.